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Asthma is a heterogeneous disorder that results in recurrent attacks of breathlessness,
coughing, and wheezing that affects millions of people worldwide. Although the
precise causes of asthma are unclear, studies suggest that a combination of
genetic predisposition and environmental exposure to various allergens and pathogens
contribute to its development. Currently, the most common treatment to control asthma
is a dual combination of β2-adrenergic receptor agonists and corticosteroids. However,
studies have shown that some patients do not respond well to these medications, while
others experience significant side effects. It is reported that the majority of asthmas are
associated with T helper type 2 (TH2) responses. In these patients, allergen challenge
initiates the influx of TH2 cells in the airways leading to an increased production of
TH2-associated cytokines and the promotion of allergy-induced asthma. Therefore,
biologics that target this pathway may provide an alternative method to treat the allergic
airway inflammation associated with asthma. As of now, only two biologics (omalizumab
and mepolizumab), which target immunoglobulin E and interleukin-5, respectively, are
FDA-approved and being prescribed to asthmatics. However, recent studies have
reported that targeting other components of the TH2 response also show great promise.
In this review, we will briefly describe the immunologic mechanisms underlying allergic
asthma. Furthermore, we will discuss the current therapeutic strategies used to treat
asthma including their limitations. Finally, we will highlight the benefits of using biologics
to treat asthma-associated allergic airway inflammation with an emphasis on the potential
of targeting cytokine alarmins, especially thymic stromal lymphopoietin.
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INTRODUCTION
Asthma is a heterogeneous disorder characterized by airflow obstruction, bronchial hyper-
responsiveness, and airway inflammation, resulting in recurrent attacks of breathlessness,
coughing, and wheezing (Busse and Lemanske, 2001). According to the World Health
Organization, an estimated 235 million people currently suffer from asthma (Asthma, 2015a).
The prevalence of asthma has dramatically increased in developed countries over the past
decade (Asthma, 2015b). In the United States alone approximately 9.3% of all children
and 8% of all adults currently have asthma, for a total of 25 million people. Additionally,
asthma exerts a tremendous economic burden, costing the US tens of billions of dollars
in medical costs, lost school and work days, and early deaths (Asthma, 2015b). Thus, the
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development of effective therapies to treat asthma is of utmost
importance.
Although the precise causes of asthma are unclear, studies
suggest that a combination of genetic predisposition and
environmental exposure to various allergens and pathogens
contribute to its development (Gilmour et al., 2006; Brauer
et al., 2007; Vercelli, 2008; Bush and Peden, 2009). Risk factors
thought to be associated with asthma include exposure to
inhaled substances such as both indoor (house dust mite) and
outdoor allergens (pollen), tobacco smoke, chemical irritants,
and certain types of air pollution (Gilmour et al., 2006; Brauer
et al., 2007; Bush and Peden, 2009). In addition, exposure to
certain respiratory viruses early in life may contribute to the
development of asthma at a later age. For instance, infants and
young children who suffer from wheezing illnesses caused by
rhinovirus infections were found to be more likely to develop
asthma by age 6 (Jackson et al., 2008). Similarly, severe lower
respiratory viral infections during infancy were found to promote
asthma in children at high atopic risk (Kusel et al., 2007).
Finally, specific polymorphic variants of several genes including
a disintegrin and metalloproteinase (ADAM) 33 (Holgate et al.,
2007), G protein–coupled receptor for asthma susceptibility
(GPRA; Laitinen et al., 2004), and human leukocyte antigen
(HLA)-G (Nicolae et al., 2005) have been shown to be associated
with asthma susceptibility. Collectively, these studies suggest that
asthma is a remarkably complex disease which can be promoted
by several distinct factors. The complexity of asthma and the
obvious importance of both genetic and environmental factors
in its development suggest that diverse treatment strategies may
be necessary in order to target the pathways that promote specific
forms of the disease.
Currently, the most common treatment to control asthma
is a combination of β2-adrenergic receptor agonists, which
relax airway smooth muscle, and corticosteroids, which reduce
inflammation of the airways (National Heart Lung and Blood
Institute, 2007). Anti-leukotrienes are also often added to the
treatment regimen when β2-agonists and corticosteroids fail
to adequately control the symptoms. Although this therapeutic
program is generally effective for most patients, there are
several concerns. Studies have shown that some patients with
severe asthma do not respond as well to β2-adrenergic receptor
agonists or corticosteroids (Chan et al., 1998), In some cases,
this can be attributed to single nucleotide polymorphisms in
specific asthma-related genes (Drazen et al., 1999; Israel et al.,
2000; Sampson et al., 2000; Tantisira et al., 2004). Moreover,
most likely because of their unspecific mechanisms of actions,
inhaled corticosteroids may cause serious side effects, especially
if taken systemically or in large doses (Chung and O’Byrne,
2003; Dahl, 2006). Therefore, the development of biologics that
provide a more targeted treatment option would greatly benefit
patients who fail to respond to traditional therapeutics or are
experiencing significant side effects. The purpose of this article is
to describe the potential benefits of employing biologic therapies
and to highlight the cellular pathways they may target. First,
we will review the immunologic mechanisms known to promote
airway inflammation in the context of allergic asthma. Next, we
will describe conventional treatment options and review their
benefits, limitations, and possible side effects. Finally, we will
introduce the potential of biologic therapies in treating allergic
airway inflammation and highlight the cellular mechanisms
through which they may operate.
IMMUNOLOGIC MECHANISMS
UNDERLYING ASTHMA
There are several phenotypes of asthma, each with its own natural
history, clinical, and physiological features, pathobiology, and
response to different therapies (Wenzel, 2012). The complex
immunologic mechanisms responsible for promoting these
various forms of asthma have been extensively discussed (Cohn
et al., 2004). However, for the purpose of this article, we will
briefly summarize the mechanisms underlying asthma, focusing
on the role of T helper type 2 (TH2)-associated cytokines in the
promotion of asthma, and highlight the therapeutic potential of
targeting these pathways (Figure 1). The majority of asthmas
are associated with T helper type 2 responses (Wenzel, 2012).
In asthmatic patients, allergen challenge initiates the influx of
TH2 cells in the airways leading to an increased production
of TH2-associated cytokines including IL-4, IL-5, and IL-13
which promote the detrimental inflammation associated with
asthma (Lloyd and Hessel, 2010). IL-4 production causes B
cells to undergo IgE isotype switching resulting in an increase
in circulating IgE, which sensitizes mast cells, eosinophils, and
basophils to allergen exposure. Upon secondary exposure to the
allergen, degranulation of these cells results in the release of
histamine and reactive oxygen species leading to smooth muscle
contraction, mucous secretion, and vasodilatation (Hamid and
Tulic, 2009). In addition, IL-5 promotes the growth, maturation,
and activation of eosinophils, which release potent cytotoxic
proteins responsible for tissue destruction in the airways
(Leckie et al., 2000). Finally, IL-13 also enhances IgE isotype
switching, increases epithelial permeability, stimulates mucus
production, and promotes airway hyper-responsiveness (Ingram
and Kraft, 2012). Collectively, the activation of TH2 cells and
the production of TH2-associated cytokines represent critical
effector functions that are capable of promoting an asthmatic
response.
The known role of TH2 cells and type 2 cytokines in
promoting inflammation and asthma pathogenesis make the
pathways that regulate these responses prime targets for anti-
asthma therapies. Recent studies have found that cytokine
alarmins, including thymic stromal lymphopoietin (TSLP),
IL-25, and IL-33, produced by epithelial cells and some
hematopoietic cells play important roles in the promotion of
TH2 cell development and the initiation of asthma pathogenesis
(Paul and Zhu, 2010). Therefore, therapies that target these
molecules may hold the most promise as they could potentially
shut down multiple components of the TH2 response responsible
for asthma. In summary, as our knowledge of TH2 pathways
increases, we are identifying new molecular targets which are
involved in the initial stages of asthma pathogenesis. We will
discuss the therapeutic potential of targeting these molecules in
subsequent sections.
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FIGURE 1 | Following exposure to allergens, epithelial cells release cytokine alarmins including thymic stromal lymphopoietin (TSLP), IL-25, and IL-33.
Cytokine alarmins promote the production of type 2 cytokines (IL-4, IL-5, and IL-13) by immune cells of both the innate and adaptive immune systems. Moreover,
crosstalk between these two branches further promotes TH2 cytokine-mediated inflammation including production of IgE and the expansion of eosinophil
populations, events that contribute to asthma pathogenesis. The anti-IgE monoclonal antibody omalizumab and the anti-IL-5 monoclonal antibody mepolizumab, the
only biologics which have been approved by the FDA, provide effective long-term control and reduce the steroid requirement in patients with severe allergic asthma.
Moreover, biologics targeting TSLP and IL-13 are currently undergoing clinical trials. Although biologics targeting the cytokine alarmins IL-25 and IL-33 have shown
promise in murine studies, further studies are needed to determine their therapeutic potential. The development of biologics to treat allergy-associated asthma will aid
in the eventual goal of creating novel personalized treatment regimens.
CURRENT THERAPEUTIC STRATEGIES
The current pharmacological agents used to treat asthma are
focused on relieving airway obstruction and reducing chronic
airway inflammation (National Heart Lung and Blood Institute,
2007). Inhaled β2-adrenergic receptor agonists are the most
commonly used bronchodilators employed to treat asthma
because of their rapid and potent effects in relaxing airway
smooth muscle via direct stimulation of β2-receptors on airway
smooth muscles (Cazzola et al., 2011). The most commonly
used anti-inflammatory agents used to treat asthma consist
of inhaled corticosteroids, which are beneficial but can have
significant side effects. In addition, anti-leukotrienes, which have
both anti-inflammatory and bronchoprotective effects, are used
to alleviate symptoms either by themselves or in combination
with inhaled glucocorticosteroids by inhibiting essential enzymes
required for leukotriene production or by blocking their effects
on target cells such as bronchial smooth muscle (Dahlén, 2006;
National Heart Lung and Blood Institute, 2007). Despite their
overall effectiveness, many current treatments focus heavily on
targeting late phase events that promote inflammation, including
histamine production and airway hyper-responsiveness, rather
than on the initiation of the TH2 response (Holgate et al.,
2007). Understanding the innate immune mechanisms that
initiate TH2 cytokine-mediated inflammation would allow for the
development of novel and more effective drugs that target the
early stages of asthma pathogenesis.
Despite the efficacy of current therapies for most patients
with asthma, clinical studies have shown that there is a variable
response. In around 5–10% of people with asthma, the disease
symptoms remain inadequately controlled even after treatment
with inhaled corticosteroids, β2-adrenergic receptor agonists,
and oral leukotriene inhibitors (Pelaia et al., 2012). Moreover,
a retrospective study found that steroid insensitive (SI) asthma
is quite common (25%) in adolescents with severe asthma
(Chan et al., 1998). One possible reason for this variation in
responses to asthma treatments are polymorphic variants in
specific asthma-related genes; in fact previous pharmacogenetic
studies suggest that genetics may contribute to as much as 60–
80% of the variability observed in treatment response (Weiss
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et al., 2006). For example, it has been reported that variation
in the corticotropin-releasing hormone receptor 1 (CRHR1)
was associated with an enhanced response to corticosteroid
therapy (Tantisira et al., 2004). Similarly, a single nucleotide
polymorphism in the LTC4 synthase gene promoter may be
associated with asthma that responds well to treatment with
leukotriene receptor antagonists (Sampson et al., 2000). However,
there are also polymorphic variants which are associated with a
decreased response to certain pharmacological agents. Patients
who were found to be homozygous for arginine at codon 16
of the β2-adrenergic receptor did not respond as well to the
β2-adrenergic receptor agonist albuterol compared to patients
without this polymorphism (Israel et al., 2000). Furthermore,
sequence variants of the core promoter of ALOX5, the gene that
codes for 5-lipoxygenase, an essential enzyme for leukotriene
production, were associated with decreased clinical responses to
ALOX5 inhibitors (Drazen et al., 1999). Collectively, these studies
highlight the need for novel treatment options for patients who
are found to be non-responsive to current therapies.
In addition to limitations of efficacy, the side effects of the
most common therapeutics currently used to treat and control
asthma represent another major concern. For example, long-
term use of inhaled corticosteroids has been associated with
several negative consequences including growth suppression,
reduced bone density, glaucoma, cataracts, and skin thinning
(Dahl, 2006). However, the severity and permanence of these side
effects is still up for debate. For instance, although it is known
that asthmatic children treated with inhaled corticosteroids
experience suppressed growth before puberty, whether final adult
height is affected is still unclear (Doull, 2004; Kelly et al., 2012).
Similarly, whether patients who take inhaled corticosteroids
suffer from a permanent reduction in bone density and are
at an increased risk for osteopenia has not been determined
(Peters, 2006; Kelly et al., 2008). Interestingly, several studies
have suggested that inhaled corticosteroids, even when taken at
relatively low doses, increase the risk of developing posterior
subcapsular cataracts (Ernst et al., 2006; Wang et al., 2009).
Additionally, although side effects are not common with inhaled
β2-adrenergic receptor agonist therapy, it is reported that muscle
tremors, tachycardia, and palpitations can occur in patients
undergoing treatment (Chung and O’Byrne, 2003). In summary,
although the long-term effects of current treatments for asthma
remain up for debate and aremost likely dependent on the dosage
and duration of the treatment, new therapies would greatly
benefit patients suffering from asthma, especially those who
would otherwise require a high dosage of inhaled corticosteroid
and β2-adrenergic receptor agonists.
THE BENEFITS OF BIOLOGICS
While many of the therapies highlighted above target non-
specific inflammatory pathways, biologics may offer physicians
a personalized and more specific approach to treating allergic
airway inflammation. To date, the only two biologics that are
FDA-approved and being used to treat asthma are the humanized
monoclonal IgE-targeting antibody omalizumab (Xolair) and the
humanized monoclonal IL-5-targeting antibody mepolizumab
(Nucala; Figure 1). Omalizumab works by binding to IgE,
preventing its interaction with the high-affinity FcεRI expressed
by mast cells, basophils, eosinophils, and dendritic cells, all of
which are important in the pathogenesis of asthma (Busse and
Lemanske, 2001). Studies have found that omalizumab provides
effective long-term control and reduces the steroid requirement
in patients with severe allergic asthma; additionally, omalizumab
was found to be well tolerated (Soler et al., 2001; Lanier et al.,
2003). Mepolizumab, works by targeting IL-5, an important TH2
cytokine that promotes the growth, maturation, and activation
of eosinophils (Leckie et al., 2000). Mepolizumab was found
to significantly reduce asthma exacerbations as measured by
a variety of parameters including forced expiratory volume in
1 second (FEV1) and scores on the St. George’s Respiratory
Questionnaire and the 5-item Asthma Control Questionnaire
(ACQ5; Leckie et al., 2000; Ortega et al., 2014). In addition, the
safety profile of mepolizumab was similar to that of the placebo
(Ortega et al., 2014).
In addition to anti-IgE and anti-IL-5 therapies, antibodies
against the TH2-associated cytokine IL-13 may also hold great
therapeutic potential. IL-13 produced in the airway promotes
the survival and migration of eosinophils, the activation of
macrophages, the production of mucus by airway epithelial cells,
the transformation of airway fibroblasts tomyofibroblasts leading
to collagen deposition and tissue remodeling, and airway hyper-
responsiveness, all of which are key features of allergic asthma
(Ingram and Kraft, 2012). It is reported that lebrikizumab,
a humanized monoclonal anti-IL-13 antibody that specifically
binds to IL-13 and inhibits its function, was associated with
improved lung function as measured by FEV1 but did not reduce
asthma exacerbations or symptoms as measured by the ACQ5
(Corren et al., 2011). Additionally, the study found that periostin,
a matricellular protein produced by bronchial epithelial cells in
response to IL-13, could be used to predict patient response
to lebrikizumab (Corren et al., 2011). This finding is especially
important as different biologics would be expected to be more
effective in treating different asthma phenotypes (Wenzel, 2012).
Although treatments that inhibit the activity of TH2-associated
cytokines and IgE show great potential, they target the later stages
of the TH2 response, after TH2 and other inflammatory cells have
already been recruited to and are active in the airways. Therefore,
it is possible that targeting the more upstream events of asthma
pathogenesis may represent a more effective strategy.
For this reason, thymic stromal lymphopoietin (TSLP) is an
especially promising target. TSLP is a tissue-derived cytokine
which is released by bronchial epithelial cells; consequently
its effects are upstream of TH2-associated cytokine production
by TH2 cells, mast cells, and basophils (Figure 1). TSLP has
been found to be overexpressed in patients with asthma, atopic
dermatitis, and food allergies, and specific polymorphic variants
have been found to be associated with asthma and airway
hyper-responsiveness (Ying et al., 2005; He et al., 2009). In
addition, TSLP has been found to be crucial for driving TH2
cytokine-mediated inflammation in multiple murine model
systems (Siracusa et al., 2011; Pelaia et al., 2012). For example,
TSLP knockout mice fail to develop an inflammatory lung
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response to inhaled antigens in a murine model of allergic
asthma (Al-Shami et al., 2005). Furthermore, it has been
demonstrated that dendritic cells that are activated by TSLP
prime naïve CD4+ T cells to differentiate into TH2 cells
and produce the TH2 cell-attracting cytokines TARC (thymus
and activation-regulated chemokines) and MDC (macrophage-
derived chemokines; Soumelis et al., 2002; Ito et al., 2005).
Even in the absence of TH2 cells, TSLP can act synergistically
with IL-1 and tumor necrosis factor and stimulate mast cells to
produce high levels of TH2 cytokines in response to inflammatory
cytokines or physical injury (Allakhverdi et al., 2009). Moreover,
TSLP has been shown to enhance TH2-associated cytokine
expression in human innate helper 2 cells (ILC2) from peripheral
blood and nasal polyps and to activatemouse lung and skin ILC2s
(Halim et al., 2012; Mjösberg et al., 2012; Kim et al., 2013). TSLP
also uniquely promotes TH2 responses by acting on progenitor
cells. For example, circulating human CD34+ progenitor cells
were found to express the TSLP receptor and in response to this
cytokine, rapidly release high levels of proinflammatory TH2-
associated cytokines and chemokines (Allakhverdi et al., 2009).
Additionally, TSLP also appears to influence the hematopoietic
programming of progenitor cells in the bone marrow. For
example, it is reported that TSLP acts on bone marrow-resident
progenitors to elicit the expansion of a functionally distinct
population of basophils that promote TH2 cytokine-mediated
inflammation (Siracusa et al., 2011). Therefore, the ability of
TSLP to promote inflammation via targeting both innate and
adaptive immune cells as well as altering hematopoiesis suggests
it may represent a potent therapeutic target. In fact, a recent
study found that treating patients with mild allergic asthma with
AMG 157, a human anti-TSLP monoclonal antibody, reduced
allergen-induced bronchoconstriction and airway inflammation
both before and after allergen challenge; moreover there was no
significant difference in the number of adverse events between
the AMG 157 and the placebo group (Gauvreau et al., 2014).
Although more studies need to be done to assess the clinical
benefits of anti-TSLP antibody treatment, these initial results
indicate that targeting TSLP may be an effective approach for
treating allergic airway inflammation. Although the specific
immunologic pathways involved in the initiation of asthma
pathogenesis remain to be fully defined, gaining a better
understanding of these pathways will guide the development of
novel therapeutics that target multiple components of the TH2
response responsible for allergic asthma.
TARGETING ADDITIONAL CYTOKINE
ALARMINS
As mentioned previously, the cytokine alarmins IL-25 and IL-
33 are similar to TSLP in that they also play important roles
in the promotion of asthma pathogenesis and act upstream
of multiple components of the TH2 response (Figure 1; Paul
and Zhu, 2010; Beale et al., 2014). One study, which employed
a murine model of TH2-type/eosinophilic allergic asthma,
reported that IL-25 induces local inflammation by activating
airway structural cells including epithelial cells as well as
immune cells such as TH2 cells and eosinophils that drive
airway inflammation (Suzukawa et al., 2012). Moreover, IL-25
deficiency resulted in a reduction in the number of eosinophils
in bronchoalveolar lavage fluids, suppressed airway hyper-
responsiveness after methacholine challenge, and resulted in
lower levels of antigen-specific IgG1 and IgE (Suzukawa et al.,
2012). Further highlighting its importance in promoting TH2
cell-mediated inflammation, IL-25 was found to promote the
proliferation of human TH2 memory cells and enhanced their
ability to produce TH2 cytokines after stimulation with TSLP-
activated dendritic cells (DCs; Wang et al., 2007). Similarly, IL-
33 has also been associated with asthma and the TH2 response.
For example, higher levels of IL-33 transcripts were detected
in biopsies from asthmatic compared with control subjects
(Prefontaine et al., 2009). Further, adoptive transfer of dendritic
cells pre-treated with IL-33 exacerbated lung inflammation in a
DC-driven model of allergic airway inflammation demonstrating
the importance of IL-33 in promoting asthma pathogenesis
(Besnard et al., 2011). More recently, IL-25 and IL-33 promote
the population expansion of IL-5- and IL-13-producing ILC2s
that have been shown to promote pathogenesis in mouse models
of allergic asthma and atopic dermatitis (Wolterink et al., 2012;
Salimi et al., 2013). Therefore, similar to TSLP, IL-25, and IL-
33 act upstream of TH2-associated cytokine and IgE production,
making them enticing targets for biologics. However, although
several murine studies have shown that targeting IL-25 and IL-
33 with depleting antibodies may be effective in reducing airway
inflammation and airway hyper-responsiveness, human trials
have yet to yield promising results (Ballantyne et al., 2007; Liu
et al., 2009). Nevertheless, the potential of anti-IL-25 and anti-
IL-33 therapeutics to suppress multiple components of the TH2
response responsible for asthma pathogenesis warrants more
attention.
SUMMARY
Asthma is an incredibly complex and heterogeneous disorder
that affects millions of people around the world (Asthma,
2015a). Although the current pharmacological agents used to
treat asthma, which include inhaled β2-adrenergic receptor
agonists, inhaled corticosteroids, and anti-leukotrienes, are
generally effective for the majority of asthma patients, there is
a select group who are unresponsive (Chan et al., 1998; Chung
and O’Byrne, 2003). In addition, most likely because of their
unspecific mechanisms of actions, these therapies have been
associated with serious side effects, especially if taken systemically
or in large doses (Chung and O’Byrne, 2003; Dahl, 2006). For
these reasons, it is imperative that new types of therapeutics to
treat asthma are developed. Biologics may offer physicians amore
personalized approach to treating allergy-associated asthma. In
addition to the already FDA-approved biologics omalizumab
and mepolizumab, therapies that target IL-13 are undergoing
clinical trials (Soler et al., 2001; Lanier et al., 2003; Corren et al.,
2011; Ingram and Kraft, 2012; Ortega et al., 2014). Critically,
since recent studies have found that there are multiple classes
of asthma, each with its own unique characteristics, it would
be expected that certain biologics would be more effective than
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others in treating each phenotype (Wenzel, 2012). Perhaps the
most exciting therapeutic target is the cytokine alarmin TSLP
because of its ability to alter hematopoiesis and to promote
inflammation via targeting both innate and adaptive immune
cells (Soumelis et al., 2002; Ito et al., 2005; Siracusa et al., 2011;
Kim et al., 2013). Additionally, because TSLP acts upstream of
TH2-associated cytokine and IgE production, it may potentially
act as a “master switch” in that inhibiting its actions may shut
down multiple components of the TH2 response responsible
for the initiation of asthma pathogenesis. Moreover, despite
the lack of human studies, biologics that target IL-25 and IL-
33 also have the potential suppress the TH2 response in a
similar fashion and should not be neglected. Because biologics
that target upstream components of the TH2 response are in
the early stages of development, it is difficult to predict any
complications that may arise. Since these molecules regulate
multiple aspects of the TH2 response, their inhibition could lead
to non-desired effects including increased susceptibility to certain
types of infections, especially those caused by parasites. However,
the potential of targeting these alarmins to treat asthma should
not be understated. Although our understanding of the pathways
that drive asthma is still incomplete, we are beginning to grasp the
potential of using biologics to treat allergic airway inflammation.
As additional pathways involved in asthma pathogenesis are
uncovered, therapeutics that target these pathways are developed,
which would aid in the eventual goal of creating personalized
treatment regimens for each patient specific to his or her disease
phenotype.
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